Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:CLDX NASDAQ:FOLD NASDAQ:LGND On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$29.75+2.4%$28.34$25.56▼$36.45$4.80B0.471.73 million shs1.39 million shsCLDXCelldex Therapeutics$22.46+2.0%$22.12$14.40▼$47.00$1.46B1.221.31 million shs1.80 million shsFOLDAmicus Therapeutics$7.61+0.1%$6.35$5.51▼$12.65$2.34B0.534.47 million shs3.92 million shsLGNDLigand Pharmaceuticals$159.08+1.1%$131.34$93.58▼$161.93$3.08B0.85310,662 shs234,074 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes+0.31%+2.83%+7.51%-0.99%+2.83%CLDXCelldex Therapeutics+5.41%-11.71%-1.52%+8.21%-38.97%FOLDAmicus Therapeutics+2.70%+6.74%+22.19%+22.19%-37.14%LGNDLigand Pharmaceuticals+1.33%+2.29%+18.76%+54.83%+48.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKSAlkermes4.8083 of 5 stars4.41.00.04.23.52.51.9CLDXCelldex Therapeutics1.6938 of 5 stars3.43.00.00.01.70.00.0FOLDAmicus Therapeutics4.3671 of 5 stars3.42.00.04.33.60.01.9LGNDLigand Pharmaceuticals4.0983 of 5 stars1.53.00.04.44.02.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.83Moderate Buy$41.0837.73% UpsideCLDXCelldex Therapeutics 2.78Moderate Buy$46.67107.01% UpsideFOLDAmicus Therapeutics 2.80Moderate Buy$16.22112.47% UpsideLGNDLigand Pharmaceuticals 3.00Buy$157.00-1.12% DownsideCurrent Analyst Ratings BreakdownLatest CLDX, ALKS, LGND, and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/20/2025CLDXCelldex TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$44.00 ➝ $38.008/20/2025CLDXCelldex TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$56.00 ➝ $48.008/20/2025CLDXCelldex TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$64.00 ➝ $62.008/20/2025CLDXCelldex TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $42.008/8/2025LGNDLigand PharmaceuticalsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$155.00 ➝ $185.007/30/2025ALKSAlkermesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$40.00 ➝ $42.007/30/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$145.00 ➝ $162.007/29/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.007/21/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$46.007/21/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$45.007/17/2025FOLDAmicus TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.56B3.16$2.73 per share10.93$9.84 per share3.03CLDXCelldex Therapeutics$7.02M213.26N/AN/A$9.87 per share2.28FOLDAmicus Therapeutics$528.29M4.45N/AN/A$0.66 per share11.57LGNDLigand Pharmaceuticals$167.13M18.62$1.64 per share96.62$42.28 per share3.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0814.3421.771.6623.15%24.86%17.14%10/23/2025 (Estimated)CLDXCelldex Therapeutics-$157.86M-$3.01N/AN/AN/A-3,446.88%-27.61%-26.20%11/5/2025 (Estimated)FOLDAmicus Therapeutics-$56.11M-$0.12N/A17.76N/A-6.67%-5.07%-1.23%11/5/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A42.80N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)Latest CLDX, ALKS, LGND, and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025CLDXCelldex Therapeutics-$0.86-$0.85+$0.01-$0.85$1.13 million$0.73 million8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ACLDXCelldex TherapeuticsN/AN/AN/AN/AN/AFOLDAmicus TherapeuticsN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85CLDXCelldex TherapeuticsN/A19.6719.67FOLDAmicus Therapeutics1.923.212.29LGNDLigand PharmaceuticalsN/A5.455.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%CLDXCelldex TherapeuticsN/AFOLDAmicus TherapeuticsN/ALGNDLigand Pharmaceuticals91.28%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%CLDXCelldex Therapeutics4.40%FOLDAmicus Therapeutics2.20%LGNDLigand Pharmaceuticals7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableCLDXCelldex Therapeutics15066.41 million63.49 millionOptionableFOLDAmicus Therapeutics480308.24 million301.46 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableCLDX, ALKS, LGND, and FOLD HeadlinesRecent News About These CompaniesA Fresh Look at Ligand Pharmaceuticals (LGND) Valuation Following $400 Million Convertible Note Offering and Capital Structure ShiftAugust 22 at 10:33 AM | finance.yahoo.comConnor Clark & Lunn Investment Management Ltd. Reduces Position in Ligand Pharmaceuticals Incorporated $LGNDAugust 22 at 3:38 AM | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Sold by Vanguard Group Inc.August 22 at 3:18 AM | marketbeat.comLigand Pharmaceuticals Incorporated $LGND Shares Bought by Aberdeen Group plcAugust 20 at 5:20 AM | marketbeat.comLigand Pharmaceuticals Inc (LGND) Announces Participation in Upcoming Investor Conferences | ...August 19 at 6:31 PM | gurufocus.comLigand Pharmaceuticals to Participate in Upcoming Investor Conferences in September 2025August 19 at 4:51 PM | quiverquant.comQLigand to Participate in September Investor ConferencesAugust 19 at 4:00 PM | globenewswire.comRussell Investments Group Ltd. Has $14.23 Million Stake in Ligand Pharmaceuticals Incorporated $LGNDAugust 19 at 4:54 AM | marketbeat.comPublic Sector Pension Investment Board Grows Stock Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)August 18, 2025 | marketbeat.comLigand Pharma Completes $460M Convertible Notes OfferingAugust 14, 2025 | msn.comLigand Announces Closing of Convertible Senior Notes OfferingAugust 14, 2025 | globenewswire.comUS Bancorp DE Purchases 3,301 Shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)August 14, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Sets New 52-Week High - Should You Buy?August 13, 2025 | marketbeat.comLigand Pharmaceuticals (NASDAQ:LGND) Shares Gap Down - Should You Sell?August 12, 2025 | marketbeat.comLigand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares Purchased by Townsquare Capital LLCAugust 12, 2025 | marketbeat.comAnalysts Are Bullish on Top Healthcare Stocks: Insmed (INSM), Ligand Pharma (LGND)August 12, 2025 | theglobeandmail.comLigand Pharmaceuticals to offer $400M convertible senior notes in private placementAugust 12, 2025 | msn.comLGND: Getting In Tune with MedTechAugust 12, 2025 | msn.comLigand prices $400M convertible debt offeringAugust 12, 2025 | msn.comLigand Pharmaceuticals Inc (LGND) Announces Pricing of $400 Million Convertible Senior Notes | ...August 12, 2025 | gurufocus.comLigand Pharmaceuticals Inc (LGND) Announces Pricing of $400 Million Convertible Senior Notes | ...August 12, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLDX, ALKS, LGND, and FOLD Company DescriptionsAlkermes NASDAQ:ALKS$29.75 +0.69 (+2.37%) Closing price 04:00 PM EasternExtended Trading$29.75 0.00 (0.00%) As of 05:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Celldex Therapeutics NASDAQ:CLDX$22.46 +0.44 (+2.00%) Closing price 04:00 PM EasternExtended Trading$22.78 +0.32 (+1.42%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.Amicus Therapeutics NASDAQ:FOLD$7.61 +0.01 (+0.13%) Closing price 04:00 PM EasternExtended Trading$7.62 +0.01 (+0.13%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.Ligand Pharmaceuticals NASDAQ:LGND$159.08 +1.77 (+1.13%) Closing price 04:00 PM EasternExtended Trading$159.07 -0.01 (-0.01%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet’s Breakout Potential: From Laggard to AI Leader After Earnings Miss, Walmart Is Still a Top Consumer Staples Play Should You Join Buffett and Invest in Constellation Brands? Can Identity Security Fuel CrowdStrike’s Next Growth Phase? 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Shopify’s Risk-Reward Profile Is Suddenly Red Hot 3 Reasons Salesforce Is a Bargain Right Now Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access